Oncolytic virus therapy
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsZongSheng Guo, David Bartlett, Zuqiang Liu, Mathilde Feist
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus (“OV-induced T cells”), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.
Claims17
A method of treating a subject suffering from cancer, wherein the cancer is melanoma, wherein said method comprises:
- (a) administering, to the subject, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer, wherein the oncolytic virus is a herpes simplex virus (HSV) and the HSV comprises a nucleic acid encoding granulocyte macrophage colony-stimulating factor (GM-CSF);
- and
- (b) following step (a), administering, to the subject, an effective amount of ex vivo expanded T cells that were expanded ex vivo from one or more T cells isolated from the cancer of the subject, wherein the one or more T cells were isolated after step (a).
Dependencies are inferred from the claim text.